Realm Therapeutics shares crater — again — on a failed PhII atopic dermatitis study
A little over a year after Realm Therapeutics put together a transatlantic syndicate to back a $26 million venture round, the biotech has been watching its stock $RLM crater after a Phase II failure for their lead therapy. And this is their second Phase II flop in 5 months.
Researchers for the Malvern, PA-based biotech had hoped to get some solid supporting data from their mid-stage study of PR022 in atopic dermatitis — planning to recruit 120 trial subjects to test the topical gel — but they couldn’t see any improvement over the control arm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.